Atorvastatin for moderate to severe thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether atorvastatin, a common cholesterol medicine, can reduce inflammation and improve eye symptoms in people with moderate-to-severe thyroid eye disease. It may help by calming the immune response that causes the eye problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have moderate-to-severe thyroid eye disease that is currently active (with symptoms like pain, redness, or swelling).
- You must not have taken any cholesterol-lowering drugs (like statins) in the past 3 months.
- You must be willing to attend weekly clinic visits and complete follow-up for up to 48 weeks.
- Women of childbearing age must agree to use effective birth control until week 24.
- You must not have had steroid treatment for eye disease in the past 3 months, or prior eye surgery or radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether atorvastatin, a cholesterol-lowering drug, can improve symptoms of thyroid eye disease (Graves' orbitopathy). It is for people with moderate-to-severe, active eye disease who have not recently used steroids or other treatments for it.
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
This trial tests whether a statin (a cholesterol-lowering medicine) combined with vitamin D can improve active thyroid eye disease. It may help if you have both eye inflammation and high cholesterol.
This trial tests two different ways of giving a steroid medicine called methylprednisolone through an IV to treat thyroid eye disease (also called Graves orbitopathy), which causes bulging and inflammation of the eyes. The goal is to see which schedule works better and has fewer side effects.
This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Hear when a new Graves Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.